Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Unigene gains preliminary injunction in Fortical case

This article was originally published in Scrip

Executive Summary

Unigene Laboratories has said that Judge Robert Patterson of the US District Court for the Southern District of New York has entered a preliminary injunction, consented to by defendants ApotexInc and Apotex Corp, preliminarily enjoining them from launching any product proposed in their ANDA for a generic version of the innovator's nasal calcitonin product, Fortical (calcitonin salmon rDNA origin), in the US. The generics firm and the innovator have been locked in a patent battle regarding the only Orange Book-listed patent, No 6,440,392.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts